Phadia AB
$36.9K 14 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Sensible Medical Innovations Inc
Sensible Medical Innovations Inc reported $37,072.28 across General Payments, Research, and Ownership to 35 physicians and teaching hospitals across 35 transactions.
- $37.1K
- All-tracks total
- 35
- Transactions
- 35
- Recipients
- −$9.8K
- General Payments vs PY2023
Sensible Medical Innovations Inc reported $37,072.28 across all CMS Open Payments tracks (General + Research + Ownership) to 35 physicians and teaching hospitals in Program Year 2024 - ranking #1419 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $37,072.28, averaging $1.1K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer sensible-medical-innovations-inc Sensible Medical Innovations Inc
$37.1K · #1419/1,925 · 0.0% industry · PY2024
- TOT $37.1K
- RANK #1419
- SHARE 0.0%
- TXN 35
- RCP 35
- CAT 2
- GEN $37.1K
- ΔGEN −$9.8K
- TOP1 97.3%
- PY 2024
Volume peers
Nearest volume peer: Phadia AB ($36.9K)
Sensible Medical Innovations Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Sensible Medical Innovations Inc's CMS-reported General Payments decreased by $9.8K (−20.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SENSIBLE MEDICAL INNOVATIONS INCPY2023: SENSIBLE MEDICAL INNOVATIONS INCPY2024: Sensible Medical Innovations Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $46,857.08
- PY2024
- $37,072.28
What the Data Shows for Sensible Medical Innovations Inc
Rank #1419 of 1,925 companies in CMS Open Payments for 2024 belongs to Sensible Medical Innovations Inc, which reported $37,072.28 across 35 transactions to 35 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $1.1K per transaction and $1.1K per recipient.
The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $36.0K, accounting for 97.1% of this company's General Payments and 7 transactions.
General Payment Breakdown by Type
Sensible Medical Innovations Inc made 2 types of general payments. "Consulting Fee" is the largest category at $36.0K, 97.1% of General Payments.
How Sensible Medical Innovations Inc divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $36.0K | 7 | 97.1% |
| Food and Beverage | $1.1K | 28 | 2.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $36,533.45 (98.5%) of $37,072.28 in this company's General Payments records across 22 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Sensible Medical Innovations Inc
The five named recipients with the highest reported General Payments from this company
- 1
Daniel Robert Bensimhon
$36,054.31 across 9 reported transactions
- 2
Jeffrey John Oyler
$160.05 across 1 reported transactions
- 3
Robert T Cole
$131.70 across 1 reported transactions
- 4
Gregory Kent Heumann
$105.89 across 1 reported transactions
- 5
Michael Y Shen
$81.50 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Sensible Medical Innovations Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Sensible Medical Innovations Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Sensible Medical Innovations Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Crossroads Orthopedics, LLC
$36.8K 306 recipients
Compare payment profiles
Conetic Solutions, Inc.
$36.7K 474 recipients
Compare payment profiles
Nucletron B.V.
$36.7K 4 recipients
Compare payment profiles
Mauna Kea Technologies, Inc.
$36.6K 879 recipients
Compare payment profiles
Clinical Technology, Inc
$36.5K 47 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.